Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Revenue (2016 - 2025)

BioCorRx (BICX) has disclosed Revenue for 15 consecutive years, with $375929.0 as the latest value for Q4 2025.

  • Quarterly Revenue changed N/A to $375929.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 17177.1% year-over-year, with the annual reading at $797244.0 for FY2025, 10301.1% up from the prior year.
  • Revenue hit $375929.0 in Q4 2025 for BioCorRx, down from $635224.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $635224.0 in Q3 2025 to a low of $3620.0 in Q1 2024.
  • Historically, Revenue has averaged $93512.7 across 5 years, with a median of $19286.5 in 2023.
  • Biggest five-year swings in Revenue: tumbled 91.05% in 2024 and later surged 4306.38% in 2025.
  • Year by year, Revenue stood at $13613.0 in 2021, then skyrocketed by 508.83% to $82880.0 in 2022, then plummeted by 77.15% to $18938.0 in 2023, then plummeted by 78.64% to $4045.0 in 2024, then surged by 9193.67% to $375929.0 in 2025.
  • Business Quant data shows Revenue for BICX at $375929.0 in Q4 2025, $635224.0 in Q3 2025, and $178238.0 in Q2 2025.